MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
NCT07197762
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neisseria Meningitidis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- December 22, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- Emory Children's Center-Vaccine Research Clinic · Atlanta, GA
- Hope Clinic · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.